Helixgate https://validator.w3.org/feed/docs/rss2.html Insmed shelves Brinsupri in skin disease after mid-stage flop New Single‑Cell Platform Tracks RNA and Protein in Immune Signaling STAT+: A decade ago, these drugs tore apart the FDA. Today, they might be some patients’ best hope  Opinion: What American hospitals can learn from India about waste European VC Jeito gets $1.2B to help private biotechs control their ‘destiny’ When a Good Boss Is Bad for Your Career As CGT Manufacturing Scales Up, Automation and Collaboration Become Essential Daré’s CEO Wants Everyone To Invest in Women’s Health, Starting With Her Company Judge refuses to block sending abortion pill by mail for now, but says FDA must finish review Neurocrine Grows in Endocrinology, Rare Disease with $2.9B Soleno Buyout Did Eli Lilly just strike another gold mine? White House adds AbbVie’s Humira to TrumpRx alongside cheaper biosimilars High-Throughput Platform for Fast-Acting Covalent Protein Therapies Terns rebuffed a higher bid before selling to Merck STAT+: Novo Nordisk launches high-dose Wegovy STAT+: States looking to regulate use of chatbots ARPA-H selects three teams in $100M effort to repair and regrow ailing joints Terns sold to Merck for 13% lower than pharma’s initial offer because of clinical data Autoimmune Disease-Related Inflammation Reduced with ENDOtollins Drug Gilead Swallows Another Partner, Paying up to $5B for ADC Specialist Tubulis Breaking through the undruggable barrier with TPDs STAT+: Pharmalittle: We’re reading about FDA backing domestic production, another Gilead deal, and more FDA Seeks Expanded Authority To Regulate Postapproval Manufacturing Changes Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off STAT+: Gilead to buy cancer biotech Tubulis for more than $3 billion Gilead continues dealmaking streak with $3.15B Tubulis buy for ADCs BioNTech to shutter Singapore HQ after ‘comprehensive review’ CRO Fortrea launches AI-powered solution to improve trial efficiency Amgen Seeks ‘Return to Growth’ for Tepezza as More Convenient Formulation Aces Phase 3 STAT+: Merck’s experimental HIV prevention pill could be made for less than $5 a year, researchers say Opinion: STAT+: Former Geisinger CEO: U.S. health systems must replace huge numbers of people with AI  A star scientist showed that better genetics lessons could reduce racism. It was the death knell for his career High-content CRISPR activation screens identify synthetically lethal RNA-based mechanisms to sensitize cancer cells to targeted T cell cytotoxicity Minimal life by computer Home Microplastics in Human Bile Drive Mitochondrial Dysfunction and Senescence STAT+: Health insurers score major win with higher 2027 Medicare Advantage rates CRISPR at 25: The Past, Present, and Future of Genome Editing Immunotherapy Enhanced by Restoring Mitochondrial Function in Dendritic Cells Hims & Hers says limited data stolen in social engineering attack Proposed FDA budget sets Makary up to boost US biotech Amgen seeks to buoy Tepezza with injectable data in face of incoming competition STAT+: A key Medicare Advantage announcement is due today Machine Learning and Single-Cell Technology Combined to Drive High-Performance Cell Line Development Anthropic pays $400M for biotech; Praxis epilepsy drug hits in Phase 1/2 trial Takeda ends partnership with Denali amid restructuring STAT+: Pharmalittle: We’re reading about an FDA delay forcing a biotech to close, a Neurocrine deal, and more Pharma Pipeline Stalls for First Time in Decades: Citeline Nuclera launches GPCR-focused nanodisc panel  Nanotube Injector Boosts Mitochondrial Performance Through Cytoplasmic Transfer